ABSTRACT
INTRODUCTION
Cystoscopy is the most frequently used and accepted diagnostic tool in urology (1) . There are multiple indications as: hematuria, lower urinary tract symptoms evaluation, urothelial cancer follow-u p, foreign body retrieval, planning a surgery, etc. (2) . Based on these indications, it is important to notice its risks to prevent future complications. Pain, hematuria, lower urinary tract symptoms and urinary tract infection are the main adverse effects present during or after the procedure. These symptoms are associated with higher morbidity in patients and increase the cost for healthcare system (3) (4) (5) . According to García-Perdomo et al. (6) in Latin America, hematuria and urinary tract infection (UTI) incidences are 1% and 1.8% respectively, others like Jimenez-Cruz et al. (7) found 10% of UTI incidence in Spain, but it could vary between 1 and 21% according to literature (4, 5, 8, 9) .
There are studies on UTI in an ambulatory and hospital settings, identifying it as the most common nosocomial infection nowadays (10) .
Experimental studies have demonstrated the prophylaxis antibiotic´s efficacy to prevent surgical site infection and UTI in surgical settings (7, 11, 12) . According to urological guidelines, it is not mandatory to use antibiotics in procedures like cystoscopy, urodynamics and cystography in patients with sterile urine. In others, like aged patients, anomalies of the urinary tract, poor nutritional status, cigarette smoking, immunosuppression, external catheters, instrumentation of urinary tract and bacteriuria, the prophylaxis is recommended (13) (14) (15) (16) .
Currently there is no evidence to suggest antibiotic prophylaxis before cystoscopy due to a large amount of studies, heterogeneous, clinical and methodologically. The aim of this systematic review (SR) and meta-analysis (MA) was to estimate the efficacy of antibiotic prophylaxis to prevent urinary tract infection in patients who undergo a cystoscopy with sterile urine.
MATERIALS AND METHODS
This study was conducted according to the recommendations of the Cochrane Collaboration and following PRISMA Statement. The protocol was registered in the international prospective register of systematic reviews (PROSPERO): CRD42014006976.
Eligibility Criteria Studies:
We included parallel, randomized clinical trials (RCT) conducted between January 1, 1980 and December 31, 2013. Open label, cross-over trials and studies with simultaneous interventions were excluded. No language restrictions were imposed.
Participants: Female and male people older than 18 years old who underwent cystoscopy with sterile urine (negative urine culture). There were no preferences in any other demographic characteristic of participants.
Interventions: The planned interventions were: Antibiotic vs placebo; Antibiotic vs no intervention and Antibiotic vs any other intervention.
The antibiotic prophylaxis was unique administration, 30 to 60 minutes before the urological procedure. There was no restriction of dosage or type of antibiotic during the selection of the studies.
Outcomes: The primary outcome was the incidence of urinary tract infection (UTI) in placebo and treatment groups, defined as positive urine culture (>10 5 CFU/mL) plus storage bladder symptoms. The secondary outcome was asymptomatic bacteriuria (AB) defined as positive urine culture (>10 5 CFU/mL) without storage bladder symptoms. These outcomes were assessed up to 30 days after the procedure.
Exclusions: No assessment of efficacy and antibiotic as a treatment.
Information sources and search strategy
We designed a search strategy for RCTs published in Medline via PubMed, CENTRAL and EMBASE. The search strategy was specific for each database and included a combination of the medical subject headings and free text terms for urinary tract infection and cystoscopy. No language or publication status restrictions were considered. We included articles from January 1, 1980 to December 31, 2013. The full search strategies are listed in Appendix 1.
Other electronic sources were used to find additional studies, such as Clinicaltrials.gov, conference abstracts, DARE and PROSPERO. We looked for additional studies in reference lists of selected articles, contacted with authors about knowledge of published or unpublished articles.
The results of searches were crosschecked in order to eliminate duplicates.
Study selection
Two investigators independently and blindly screened the titles and abstracts to determine the potential usefulness of the articles. Eligibility criteria were applied to the full text articles during the final selection. When discrepancies occurred, an agreement was made to take a final decision. In case of no agreement, a third reviewer made the final decision.
Data collection process
Relevant data were collected by duplicate, using a standardized data extraction sheet, which contained: study design, participants, interventions and comparators and final outcomes details. Reviewers confirmed all data entries and checked at least twice for completeness and accuracy. If some information was missing, we contacted authors in order to get data completed.
Risk of bias in individual studies and across them
The risk of bias was assessed independently by two researches using the Cochrane Collaboration risk of bias tool. We solved disagreements by consensus. The "Risk of bias table" was edited using Review Manager Software Version 5.2® (RevMan) to illustrate the judgments for each study. A risk of bias summary was made to show the judgments in a cross-tabulation of study by entry. After all, we assessed the general quality by each outcome with the GRADE tool and we produced a summary of findings table.
Summary measures
Analyses were performed in Revman®5.2 and Stata®13 were needed. The Risk Ratio (RR) and the risk difference (RD) were the effect measured of the primary and secondary outcome, with 95% confidence intervals (95%CI). We performed fixed--effects Meta-analysis due to homogeneity (clinical and statistical) found in clinical trials included.
Heterogeneity between trials was assessed through the I 2 statistic. An I 2 value greater or equal to 50% could represent heterogeneity according to Higgins et al. (17) . Results were reported as forest plots showing the effect size of all the included studies with 95%CI.
Additional Analyses Subgroup Analysis
Risk of bias (low, unclear and high risk of bias)
They were performed on Stata 13. No meta--regression was performed because of the number of included studies.
Sensitivity Analysis
We undertook the sensitivity analysis based on the exclusion of each one of the trials, as well as the unpublished and the smallest trials (18) .
Publication Bias
This was not performed due to the number of studies found (less than 10 studies) according to Higgins (17) .
RESULTS
Study Selection: 94 articles were found with the search strategies designed; after exclusions, 7 studies were included in qualitative and quantitative analyses (6) (7) (8) (19) (20) (21) (22) (Figure-1) .
Characteristics of included studies: 3038 patients were found in seven studies with a median of 162 patients (45-2172). Five studies assessed UTI as primary outcome (6, 7, 19, 21, 22 ) and 6 studies assessed asymptomatic bacteriuria as primary outcome (6-8, 19, 20, 22) . Some of them measured both outcomes (6, 7, 19, 22) (Table-1 (Table-1) .
Characteristics of excluded studies: The reasons for exclusion were: different endoscopic procedures, combined procedures, not clinical trials, duplicates, inclusion of patients with positive urine culture, another research topic and antibiotic as a treatment.
Risk of bias within studies: We performed the risk of bias assessment for UTI and bacteriuria at the same time due to the close relationship between the assessment of the two outcomes:
Jimenez 
Results of individual studies by outcome Urinary Tract Infection
For antibiotic versus any other intervention, we included five studies (6, 7, 19, 21, 22) ; they showed a RR 0.52 IC95% (0.31, 0.89) (and a Risk difference of -0.012 CI95% (-0.023, -0.002)); the analysis of antibiotic compared to no intervention showed a similar effect (RR 0.55 IC95% 0.32, 0.96) (and a Risk difference of -0.012 (-0.023, -0.002)); however, different from the result of antibiotic against placebo only one study was included here (6) ( Table-2 and Figure-2). Antibiotic vs antibiotic analysis was not performed since we did not find any article.
Asymptomatic Bacteriuria
In the analysis antibiotic vs any other intervention we included six studies (6-8, 19, 20, 22) that showed a RR 0.28 IC95% (0.20, 0.39) and a risk difference (RD) -0.012 CI95% (-0.023, -0.002)); the analysis of antibiotic compared to no intervention and against placebo resulted in a similar effect (RR 0.26 IC95% 0.18, 0.38) and a Risk difference of -0.012 (-0.023, -0.002)); however, the last one had only one study included (6) ( Table-2 and Figure-2). We did not performed Antibiotic vs antibiotic analysis since we did not find any article.
Risk of bias across the studies
Most of the items assessed as "Low risk" were: attrition, selective reporting and other bias, the performance (blinding personnel and participants) and detection (blinding outcome assessment); biases showed a "No clear" assessment mostly and allocation concealment along with attrition bias showed mostly a "High risk" evaluation ( Figure-2 ).
Subgroup Analysis
We only performed the subgroup analysis related to the risk of bias assessment, based on the Cochrane tool.
Urinary Tract Infection
Regarding this outcome, we found only two studies classified as having mostly low risk 
Asymptomatic Bacteriuria
Regarding this outcome, we found two studies classified as having mostly low risk of bias: Cam 2009 and García-Perdomo 2013. They showed a RD -0.02 CI95% (-0.045, 0.005).
Two studies had unclear risk of bias: Jimenez 1993 and Tsugawa 1998. They showed RD -0.073 CI95% (-0.093, -0.053) and two studies showed a high risk of bias: Jimenez-Pacheco 2012 and Rane 2001. These two showed RD -0.014 CI95%(-0.199, -0.028) (p=0.000).
Sensitivity Analysis
The sensitivity analysis found that the inclusion of Jimenez-Cruz et al., 1993 study influenced notoriously the results. When this article is included, the meta-analysis favors prevention of UTI using antibiotic prophylaxis; however when this one is excluded, there are no differences; besides, this study carries an unclear risk of bias.
GRADE Assessment
The quality of evidence assessment was performed by the GRADE methodology and a summary of findings table was generated for both outcomes ( Table-1) . We found five studies assessing the UTI outcome as the clinically important one. These five studies had serious considerations in the risk of bias, according to the Cochrane tool but there were no other important considerations. According to this evaluation, we considered moderate quality of evidence for this outcome. There were six studies where we found similar findings for the asymptomatic bacteriuria and we graded as moderate quality of evidence according to the evaluation.
DISCUSSION

Main Findings Summary
In summary, we found 3038 patients in 7 studies included; 5 assessed UTI as primary outcome (6, 7, 19, 21, 22 ) and 6 studies assessed asymptomatic bacteriuria (6-8, 19, 20, 22) . For the primary outcome, a RR 0.52 IC95% (0.31, 0.89) was found; to asymptomatic bacteriuria a RR 0.28 IC95% (0.20, 0.39) was supported.
Interventions To Prevent Urinary Tract Infection
Physicians often think it is not necessary to incorporate antibiotics before cystoscopy because there is low incidence of UTI, however this intervention turned out to be really important when looking at the risk difference and risk of bias found in this meta-analysis. This agrees to different clinical trials that demonstrated lowering surgical site infection and UTI risk previously (7, 11, 12 recommend and prevent UTI using prophylaxis. The sensitivity analysis showed Jimenez-Cruz et al., 1993 as the most weighted study and changes results and conclusion of this research if we put it in or out of the Meta-analysis. According to the subgroup analysis, the low risk bias studies showed no differences between using or not antibiotic prophylaxis, in contrast to the unclear risk of bias studies. Clinical guidelines suggest not using prophylaxis antibiotic in patients with sterile urine who undergo cystoscopy or urodynamic studies (based on descriptive studies); on the other side, they suggest to use prophylaxis in high-risk patients (13) (14) (15) ; however it is important to remember that these recommendations are based on an expert panel and also, UTI as any other disease, has an interaction between the microorganism and the inflammatory response from the host, which will determine the symptoms according to the immunity response (23) . In Colombia, it is advised to use a first generation cephalosporine in high-risk patients due to the higher antibiotic resistance to ciprofloxacin and TMP/SMX. Indications for antibiotic in high risk patients were not measured in this MA because data were not enough based on the studies and this was not its aim.
Interventions To Prevent Asymptomatic Bacteriuria
AB is not a clinically relevant outcome because it does not imply any significant disease for the patient (24) . In the current study we found a significant reduction favoring the use of prophylaxis, however when looking at subgroup analysis based on the risk of bias assessment we found that only those studies with unclear and high risk of bias showed statistical differences, but those classified as low risk of bias showed no differences. Clinical guidelines recommended antibiotic prophylaxis to prevent urinary tract infection, however there is not an statement for preventing asymptomatic bacteriuria since this is not a major outcome in clinical practice (13) (14) (15) 25) .
All these results are according to published literature and stated hypothesis due to instrumentation of lower urinary tract. Despite of many studies evaluating AB incidence, it is just relevant for pregnant and immunosuppressed people; however, these patients are frequently excluded from clinical trials.
Limitations
Similar to other MA´s, clinical trials included were not adequately written (it does not mean bad or low quality), so the assessment could have incurred on overestimations. Currently, the Cochrane risk of bias tool is the best and more consistent tool to evaluate clinical trials because they focus on the way to conduct a clinical trial. This was helpful for the development and assessment of the articles included (17) .
Two articles had low risk of bias in most items (6, 19) . One of them showed high risk of bias in three items (sequence generation, allocation concealment and attrition bias) (8) , but the rest of them showed mostly no clear risk of bias. In general, across studies we had low risk of bias for sequence generation and attrition bias.
To notice, the most weighted study (7) had no clear risk of bias in four items (sequence generation, allocation concealment, blinding of participants, investigator and assessors); high risk in attrition bias and low risk in reporting and other biases. This is important for analyzing and interpreting results; however it had the bigger sample size, which is also relevant. When performing the subgroup analysis we found that those studies classified as low risk of bias showed no differences when using or not antibiotic prophylaxis to prevent urinary tract infections and asymptomatic bacteriuria. We believe that this is the most important issue to consider making a decision about using or not antibiotic prophylaxis before a cystoscopy.
Another important topic that limits our work is the lack of data found to perform a subgroup analysis or a meta-regression.
Despite there was no evidence of neither statistical (I 2 =0%) nor clinical heterogeneity, it is important to observe that studies used different type of antibiotics: Cefoperazone (19), Levofloxacin (6), Ceftriaxone (7), Phosphomicine trometamol (20) , Norfloxacin (21), Gentamicine (8) and Sparfloxacin (22) . This might contribute to the results and clinical application according to antibiotic resistance in each hospital or ambulatory setting.
Finally, our Meta-analysis was done for a frequent urological procedure, according to Cochrane and PRISMA methodology so we could recommend this intervention for institutions around the world.
As a conclusion, based on studies classified as low risk of bias, we found moderate evidence to not recommend the use of antibiotic prophylaxis to prevent urinary tract infection and asymptomatic bacteriuria in patients who undergo cystoscopy with sterile urine in an ambulatory setting. Nevertheless, we believe we need more well-designed, adequately powered clinical trials to assess benefits and harms of using antibiotic prophylaxis in these settings. We also suggest conducting clinical trials on patients who are likely to develop UTI to determine the most effective antibiotic/s to prevent it. These factors are: advanced age, urinary tract anomalies, poor nutritional status, cigarette smoking, immunosuppression, as well as external catheters, recurrent UTI and bacteriuria.
